News

top of page

iPharmaCenter

For sponsored articles, link insertions, and advertisements, please write to info@ipharmacenter.com

For most cost-effective consulting services:

Best-Selling Cancer Drugs 2025: Top 10 by Revenue

Best-Selling Cancer Drugs 2025: Top 10 by Revenue

Best-Selling Cancer Drugs 2025: Top 10 by Revenue

Badari Andukuri

5 days ago

EULAR Annual Meeting in London, UK | 2026 | News | Updates | iPharmaCenter

EULAR Annual Meeting in London, UK | 2026 | News | Updates | iPharmaCenter

EULAR Annual Meeting in London, UK | 2026 | News | Updates | iPharmaCenter

Badari Andukuri

May 30

American Society of Clinical Oncology (ASCO) Annual Meeting | Chicago | 2026

Badari Andukuri

May 30

China’s Biotech Momentum Grows as Pfizer Signs Multi-Billion Dollar Deal with Innovent | iPharmaCenter

Badari Andukuri

May 29

Imfinzi Secures US Approval as First Immunotherapy Combination for High-Risk NMIBC | iPharmaCenter

Badari Andukuri

May 29

CVS Caremark Shakes Up GLP-1 Coverage as Zepbound Returns to the Formulary | iPharmaCenter

Badari Andukuri

May 28

FDA Clears Decnupaz (pivekimab sunirine) for Adults With BPDCN | iPharmaCenter

Badari Andukuri

May 28

SFDA Grants Promising Drug Status to Novo Nordisk’s Frehemgo for Hemophilia A | iPharmaCenter

Badari Andukuri

May 28

Spain Explores Italy’s HTA Model to Advance EU HTA Regulation Implementation | iPharmaCenter

Badari Andukuri

May 27

AIFA Innovative Drugs April 2026: Opdivo, Yervoy, Rybrevant, Carvykti Lead New Additions | Italy Pharma | News | iPharmaCenter

Badari Andukuri

May 27

Eli Lilly Expands Infectious Disease Pipeline Through Strategic Biotech Acquisitions | iPharmaCenter

Badari Andukuri

May 26

European Atherosclerosis Society (EAS) Congress | 2026 | News | Updates | iPharmaCenter

Badari Andukuri

May 25

Germany Advances Pharmacy Reform with ApoVWG Law to Strengthen Rural Access and Healthcare Services

Badari Andukuri

May 25

FDA Approves Datroway as First TROP2-Directed ADC for First-Line Metastatic Triple-Negative Breast Cancer in Non-PD-1/PD-L1 Candidates

ipharmaservices

May 22

Europe’s Pharmaceutical Strategy in a Changing Global Order: Germany and France Push for Resilience and Competitiveness | iPharmaCenter

Badari Andukuri

May 22

Lilly’s Retatrutide Shows Breakthrough Weight Loss in Phase 3 TRIUMPH-1 Trial | iPharmaCenter

Lilly’s Retatrutide Shows Breakthrough Weight Loss in Phase 3 TRIUMPH-1 Trial | iPharmaCenter

Lilly’s Retatrutide Shows Breakthrough Weight Loss in Phase 3 TRIUMPH-1 Trial | iPharmaCenter

Badari Andukuri

May 22

Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter

Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter

Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter

Badari Andukuri

May 21

Top 10 Pharma Companies by Revenue in 2025 | iPharmaCenter

Top 10 Pharma Companies by Revenue in 2025 | iPharmaCenter

Top 10 Pharma Companies by Revenue in 2025 | iPharmaCenter

Badari Andukuri

May 21

Most-Favored-Nation Drug Pricing: $733B in U.S. Savings? | iPharmaCenter

Most-Favored-Nation Drug Pricing: $733B in U.S. Savings? | iPharmaCenter

Most-Favored-Nation Drug Pricing: $733B in U.S. Savings? | iPharmaCenter

Badari Andukuri

May 21

Baxfendy (baxdrostat) Approved in the US as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension | iPharmaCenter

Badari Andukuri

May 18

bottom of page